Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage biopharmaceutical company, has captured investor attention with its potential for significant upside, despite facing formidable challenges in its current financial metrics. The company, which operates in the biotechnology industry within the healthcare sector, is based in San Francisco, California, and focuses on developing therapies for serious infectious diseases.

Vir’s stock is currently trading at $7.71, with a 52-week range between $4.28 and $9.85. Investors are intrigued by the notable potential upside of 111.85%, as suggested by analyst target prices ranging from $12.00 to $24.00, with an average target of $16.33. This optimism is reflected in the unanimous “Buy”…